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Abstract
Background and Objective: Of three first-line anti-tuberculosis (anti-TB) drugs, isoniazid is most commonly associated with
hepatotoxicity. Differences in INH-induced toxicity have been attributed to genetic variability at several loci, NAT2, CYP2E1,
GSTM1and GSTT1, that code for drug-metabolizing enzymes. This study evaluated whether the polymorphisms in these
enzymes were associated with an increased risk of anti-TB drug-induced hepatitis in patients and could potentially be used
to identify patients at risk of liver injury.
Methods and Design: In a cross-sectional study, 2244 tuberculosis patients were assessed two months after the start of
treatment. Anti-TB drug-induced liver injury (ATLI) was defined as an ALT, AST or bilirubin value more than twice the upper
limit of normal. NAT2, CYP2E1, GSTM1 and GSTT1 genotypes were determined using the PCR/ligase detection reaction
assays.
Results: 2244 patients were evaluated, there were 89 cases of ATLI, a prevalence of 4% 9 patients (0.4%) had ALT levels
more than 5 times the upper limit of normal. The prevalence of ATLI was greater among men than women, and there was a
weak association with NAT2*5 genotypes, with ATLI more common among patients with the NAT2*5*CT genotype. The
sensitivity of the CT genotype for identifying patients with ATLI was 42% and the positive predictive value 5.9%. CT ATLI was
more common among slow acetylators (prevalence ratio 2.0 (95% CI 0.95,4.20) )compared to rapid acetylators. There was no
evidence that ATLI was associated with CYP2E1 RsaIc1/c1genotype, CYP2E1 RsaIc1/c2 or c2/c2 genotypes, or GSTM1/GSTT1
null genotypes.
Conclusions: In Xinjiang Uyghur TB patients, liver injury was associated with the genetic variant NAT2*5, however the
genetic markers studied are unlikely to be useful for screening patients due to the low sensitivity and low positive predictive
values for identifying persons at risk of liver injury.
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Introduction
China has a high incidence of tuberculosis (TB), ranking second
in the world in terms of number of cases [1]. In Xinjiang,
Northwestern China, the incidence of TB, the prevalence of smear
positive TB and the TB mortality rate are higher than the national
average and the Uyghur population are particularly at risk, but the
prevalence of drug-induced liver injury, and associated risk factors,
in this population have not been previously reported. The Directly
Observed Treatment Short-course (DOTS), recommended by
World Health Organization (WHO), constitutes the cornerstone of
the current strategy for control of tuberculosis and covers the
entire population of China. A combination of the three drugs,
isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) is used
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85905
as the first-line therapy. However, multi-drug combination therapy
is known to increase the risk of severe adverse drug reactions
(ADRs) such as hepatotoxicity, gastrointestinal disorders, allergic
reactions, arthralgia, neurological disorders, and other symptoms
[2,3]. Anti-TB drug-induced liver injury (ATLI) is the most
prevalent and serious ADR encountered in the course of TB
treatment [4]. In addition to the direct harm of ATLI, toxicity
leads to early withdrawal from treatment, compromising the
effectiveness of TB control (the China National Tuberculosis
Prevention and Control Scheme (CNTS) [5]). The pathogenic
mechanism of ATLI is still obscure [6]; a better understanding of
the pathogenic mechanism may help to guide individual treatment
and the implementation of the national anti-tuberculosis treatment
program.
Anti-tuberculosis drug-induced hepatotoxicity is caused by the
production of toxic metabolites of treatment drugs, associated with
the presence of certain genetic variants of liver enzymes. These
polymorphisms could potentially be used for screening patients
and guiding their therapy. Among the first line anti-tuberculosis
drugs, INH is more commonly associated with ATLI [7,8],
especially when used in combination with PZA. INH is
metabolized to acetylisoniazid via hepatic N-acetyltransferase 2
(NAT-2) [8]. In turn, acetylisoniazid is hydrolyzed to acetylhy-
drazine, which is probably oxidized by cytochrome
P4502E1(CYP2E1) to form some hepatotoxic intermediates
[8,9]. Direct hydrolysis of INH also generates hydrazine, a potent
hepatotoxin. The hepatotoxins generated by NAT2 or CYP2E1
may be further detoxified by glutathione S-transferases
(GSTs)(such as GSTM1and GSTT1) present in the liver [10].
Disposal of acetylhydrazine also depends on further acetylation by
NAT2 to form a non-toxic metabolite, diacetylhydrazine [8].
Therefore, studies on genetic predisposition for ATLI have
focused on a few metabolizing enzymes including NAT2,
CYP2E1, GSTM1 and GSTT1. These enzymes are polymorphic,
and the distribution of these polymorphisms varies among ethnic
groups. Persons deficient in hepatic N-acetyltransferase may
accumulate drugs that require acetylation. Individuals may be
rapid, intermediate or slow acetylators, according to their activity
of NAT2 [11], however the link between acetylator status and risk
of ATLI has been inconsistent in previous studies [8,12–22].
Inconsistent results have also been reported for the CYP2E1
polymorphisms [17,18,23–30]. Persons homozygous for
GSTM1or the GSTT1null(non-functional) genotype, which cause
lack of enzyme activity, have been found to be at increased risk of
ATLI in some studies but again the results have been conflicting
[17,29,31–38].
We assessed Uygur patients treated for TB in Xinjiang receiving
standard short-course chemotherapy recommended by WHO, two
months after they had started anti-TB treatment. We aimed to
determine the prevalence of liver injury, and to investigate the
association of genetic polymorphisms of NAT2, CYP2E1,
GSTM1 and GSTT1 with hepatotoxicity, and their potential
use for identifying patients at increased risk of liver injury.
Methods and Design
Patients
From January 2010 to May 2012, patients on TB treatment
attending clinic two months after the start of treatment, were
assessed for signs of liver injury, for risk factors for liver injury, and
for genetic markers of liver enzyme polymorphisms. A total of
2244 newly diagnosed pulmonary TB patients belonging to the
Uyghur ethnic group, from 12 counties in three regions of
Xinjiang, who were receiving standard short-course chemotherapy
recommended by WHO, who attended for a 2-month assessment,
and any patients attending clinic with suspected liver disease after
the start of treatment, prior to the 2-month visit, were invited to
participate. Signed consent was sought after explaining the aims
and procedures of the study. Patients who had signs of abnormal
liver function when they started treatment (jaundice or elevated
ALT,AST or bilirubin levels), or disease associated with liver
dysfunction, were excluded. The study protocol was approved by
the Ethics Committee of First Affiliated Hospital of Xinjiang
Medical University.
All patients were prescribed INH(600 mg), RMP(600 mg, or
450 mg if the body weight was less than 50 kg), PZA (2,000 mg),
and ethambutol (EMB) (1,250 mg) every other day in the first two
months. After the two-month, INH and RMP were continued for
a further four to six months. Retreatment patients in addition
received streptomycin (SM) (750 mg) every other day in the first
two months and continued receiving EMB for another six months.
When patients developed a suspected Adverse Drug Reaction
(ADR) (ATLI, gastrointestinal reaction, allergic reaction, nervous
system disorders, or arthralgia), their treatment was adjusted
according to the severity of the symptoms.
At the end of two months of anti-tuberculosis treatment, or if
patients presented with symptoms suggestive of hepatitis (such as
anorexia, nausea, vomiting, malaise) prior to the two-month visit,
serum ALT, AST and total bilirubin levels were measured and a
sample of each patient’s blood was stored for genotypic analysis.
Patients were interviewed using a structured questionnaire and
demographic information (gender, age, ethnicity), weight and
height, TB treatment history, anti-tuberculosis treatment induced
ADRs, clinical symptoms, and risk factors for liver disease, was
recorded. Case notes of all suspected cases of ATLI were then
reviewed and assessed by a clinician.
Definition of ATLI
In the primary analysis ATLI was defined as an ALT, AST or
bilirubin value more than two times the upper limit of normal
value [39]. The upper limit of normal used in the study was 40 U/
L for ALT, 40 U/L for AST, and 19mmol/L for total bilirubin. In
secondary analyses we considered alternative case definitions,
firstly with ATLI defined as values above three or above 5 times
the upper limit of normal, and secondly defined as ATLI if patient
ALT, AST or bilirubin levels corresponded to grade 3 or grade 4
adverse events in the The Division of AIDS table for grading the
severity of adult and pediatric adverse events (http://rsc.tech-res.
com/Document/safetyandpharmacovigilance/Table_for_Grading_
Severity_of_Adult_Pediatric_Adverse_Events.pdf).
DNA Preparation and Genotyping
Genomic DNA was extracted from, peripheral blood leukocytes
using the DNA isolation kit RelaxGene blood DNA DP319-02
(Tiangen, China) following the manufacturer’s instructions and
was stored at 220uC until used for genotyping, which was carried
out by Shanghai BioWing Applied Biotechnology Company
(http://www.biowing.com.cn).
In this study, we chose three NAT2 SNPs (SNP1rs1799929,
SNP2 rs1799930 and SNP3 rs1799931) which have been shown to
be associated with ATLI in adults treated with anti-tuberculosis
drugs. All three SNPs of NAT2 were genotyped using the PCR/
ligase detection reaction assay. The primers were 59- CCT CTC
CTGCAG GTGACC AT-39and 59- AGC ATGAAT CACTCT
GCTTC-39. Each set of ligase detection reaction probes
comprised one common probe and two discriminating probes
for the two types.
Genetic Polymorphisms of NAT2, CYP2E1, GSTM1, GSTT1
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The target DNA sequences were amplified using a multiplex
PCR method. PCR was performed in a final volume of 20 ml
containing 16 PCR buffer, 3.0 mmol/l MgCl2,2.0 mmol/l
deoxynucleotide triphosphates, 0.4 ml primers, 0.3 ml Qiagen
HotStarTaq Polymerase (QIAGEN, China), 4 ml of 16Q-solution,
and 50 ng genomic DNA. Thermal cycling was performed in
Gene Amp PCR system 9600 (PerkinElmer) with an initial
denaturation of at 95uC for 15 min, followed by 35 cycles of
denaturation at 94uC for 30 s, annealing at 62uC for 90 s, and
extension at 64uC for 90 s, followed by a final extension at 64uC
for 10 min.
The ligation reaction for each subject was carried out in a final
volume of 10 ml containing 16 NEB Taq DNA ligase buffer,
12.5 pmol of each probe mix, 0.05 ml Taq DNA ligase[NEB
Biotechnology (Beijing)], and 1 ml of multi-PCR product. A total
of 35 cycles for ligase detection reaction was performed using 35
cycles at 95uC for 2 min, 94uC for 30 s, and 50uC for 2 min. The
fluorescent products of ligase detection reaction were differentiated
by ABI sequencer 377 (ABI).
Individuals were classified into three groups as follows: rapid
acetylators (RA: a homozygote of NAT2*4), an intermediate
acetylator genotype (IA: a heterozygote of NAT2*4 and mutant
alleles) and a slow acetylator genotype (SA: a combination of
mutant alleles), as in the Table 1.
For the Rsal SNP rs2031920 genotyping of CYP2E1, the
method was the same as described above for NAT2. The primers
were 5 9-TTCATTCTGTCTTCTAACTGG-39 and 59-
CCAGTCGAGTCGACATTGTCA- 39.
In order to determine the presence or absence of the GSTM1
and GSTT1 genes, the multiplex PCR method was used, as
described above. PCR conditions were 95uC for 15 min, followed
by 35 cycles of 94uC for 30 s, 65uC for 90 s, 64uC for 90 s, and
then a final extension step at 64uC for 10 min. The PCR products
were resolved on ethidium bromide-stained 3% agarose gel. The
primers used were F: CTCAGAGTTTCTGGGGAAGC and R:
TGAGGGTAGAGAGGATATCTGATAGCA for GSTM1; F:
GTTGCTCGAGGACAAGTTCC and R: ATCTGATTTGGG-
GACCACAG for GSTT1; and AGCTGCACTGTGACAAG-
CTG and TCATTCGTCTGTTTCCCATTC for b-globin gene.
Statistical Methods
The primary analysis employed a definition of ATLI as ALT,
AST or bilirubin more than twice the upper limit of normal, in a
secondary analysis, ATLI was defined using a threshold of three
times the upper limit of normal. Association analyses were done
after excluding 297 individuals who had elevated levels of ALT,
AST or bilirubin but did not meet the criteria for ATLI that could
not be confidently ascribed as cases or non-cases, and individuals
with missing genotype data. Association of ATLI with genotypes
Table 1. Definition of acetylator status according to NAT2 genotypes.
NAT2*5 NAT2*6 NAT2*7 Acetylator genotypes Acetylator status
(rs1799929) (rs1799930) (rs1799931)
C C G G G G NAT2*4/4 RA
C T G G G G NAT2*4/5 IA
C C A G G G NAT2*4/6 IA
C C G G A G NAT2*4/7 IA
T T G G G G NAT2*5/5 SA
C T A G G G NAT2*5/6 SA
C T G G A G NAT2*5/7 SA
C C A A G G NAT2*6/6 SA
C C A G A G NAT2*6/7 SA
C C G G A A NAT2*7/7 SA
doi:10.1371/journal.pone.0085905.t001
Table 2. Characteristics of patients.
Patients with ATLI Patients with elevated Patients with normal
ALT,AST, or bilrubin ALT, AST, bilirubin
Mean age in years (range) 37 (24–56) 43 (26–60) 46 (27–61)
BMI (kg/m2) 20.3 (18.4–22.6) 21.0(19.3–22.7) 21.4 (19.5–22.9)
INH (mg/kg/day) 4.8 (4.6–5.4) 5.2 (4.7–5.8) 5.4 (4.7–6.0)
PZA (mg/kg/day) 16.1 (15.2–17.9) 17.2 (15.6–19.2) 17.9 (15.6–20.0)
Liver function tests at 2 months:
ALT 110.0 (84.3–147.0) 45.6 (37.5–54.8) 22.2 (16.8–29.0)
AST 91.4 (66.2–114.0) 42.5 (35.3–51.0) 23.0 (17.0–30.0)
bilirubin (mmol/L) 9.7 (5.1–16.5) 11.0 (6.7–14.0) 9.7 (6.0–12.5)
doi:10.1371/journal.pone.0085905.t002
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was assessed with the Cochrane-Armitage test and for acetylator
status was assessed using a test for trend. 95% confidence intervals
for the prevalence ratio were calculated using standard methods.
All statistical analyses were conducted using SPSS software version
17.0 (SPSS, Chicago, IL) or Stata version 12 (College Station,
Texas). The chi-square test was used to test for Hardy–Weinberg
equilibrium.
Results
Characteristics of Patients and Incidence of ATLI
A total of 2244 Uyghur patients who had completed 2-months
follow-up were assessed. 1858 (83%) had normal levels of AST,
ALT and bilirubin; 297 (13%) had elevated levels but did not met
the criteria for ATLI, and 89 patients (4%) were diagnosed with
ATLI. Among these 89 cases, 74 had an ALT level above two
times the upper limit of normal, and 15 patients had AST or total
bilirubin above twice the upper limit of normal. 58/89 patients
ALT, AST or bilirubin had two to three times of ULN (47 in ALT
and 11 in AST/total bilirubin), 22/89 patients had levels three to
five times of ULN (18 in ALT and 4 in AST/total bilirubin) and
9/89 had more than five times of ULN (all in ALT). Fifty-nine of
the ATLI patients reported clinical symptoms (nausea, vomiting,
anorexia or malaise). The baseline characteristics, dosages and
liver function test results of the patient are shown in Table 2. The
overall prevalence of ATLI was 4%, with increased risk among
males, and in the south of Xinjiang compared to the north
(Table 3).
NAT2 Polymorphism in Patients with and without ATLI
Genotype distributions of NAT2, CYP2E1 and GSTM1and
GSTT1 variants, among individuals who had normal levels for
liver function tests, agreed with the Hardy-Weinberg equilibrium.
NAT2*5, NAT2*6 and NAT2*7 were successfully genotyped in
1458, 1451 and 1468 subjects respectively. The NAT2*5
genotypes were associated with ATLI, with an increased
prevalence in persons with the CT genotype, compared to CC,
with a prevalence ratio of 1.70, 95% CI 1.10–2.70, Table 4. The
sensitivity of the CT genotype for predicting ATLI was 42% and
the positive predictive value 5.9%. There was no evidence of an
association of NAT2*6 or NAT2*7 genotypes with ATLI. There
was weak evidence of an association between ATLI and NAT2
acetylator status, (P-value for trend 0.06), with a 2-fold increase in
prevalence in the slow acetylator group compared to rapid
acetylators (prevalence ratio 2.0 (95% CI 0.95,4.20), Table 5).
Among the slow-acetylator genotypes, the NAT2?5/6 genotypes
was most strongly associated with ATLI (Table 6), sensitivity 25%
and positive predictive value 7.5%.
CYP2E1and GSTs Polymorphism in Patients with and
without ATLI
The C1/C1 genotype of the CYP2E1 gene was most common
in both the study groups. Only 1.9% of non-ATLI patients were
found to carry the C2/C2 genotype of the CYP2E1 gene, and no
ATLI case was found with the C2/C2 genotype (Table 7). There
was no evidence of an association of the CYP2E1 Rsa?polymorph-
ism, or the single or combined null GSTs genotypes, with ATLI.
Discussion
Xinjiang ranks second highest in terms of the prevalence of TB
and fifth highest prevalence of HIV of provinces in China.
Xinjiang is an ethnically diverse region with Uyghur people
forming 46% of the population. This is the first study to investigate
the incidence of and risk factors for hepatic injury in TB patients in
the Uhygur population. A better understanding of the risk factors
and mechanisms of drug-induced hepatotoxicity may help to
prevention this iatrogenic hepatic injury, which can be fatal. The
study in over 2000 patients found a high incidence of elevated liver
enzymes with 4% of patients with signs of liver injury after two
months of treatment. Incidence was higher among men than
women, and was higher among younger patients (under 40yrs)
Table 3. Incidence of ATLI in patients tested at 2 months.
Patients
With
ATLI1
Patients with
elevated ALT,
AST, or bilrubin2
Patients with normal
ALT, AST and
bilirubin levels3 Total
Prevalence
of
ATLI %
Prevalence
ratio
(95% CI) P-value
Region North Xinjiang 17 98 525 640 2.70% 1
South Xinjiang 72 199 1333 1604 4.50% 1.7 0.0446
(1.00,2.80)
Gender Female 29 110 846 985 2.90% 1
Male 60 187 1012 1259 4.80% 1.6 0.0282
(1.00,2.50)
Treatment Re-treatment 4 32 164 196 2.00% 1
history Primary 85 265 1694 2044 4.20% 2 0.1471
(0.76,5.50)
Age in years ,40years 52 136 803 991 5.20% 1
40–59years 18 86 537 641 2.80% 0.54 0.0175
(0.32,0.91)
60+years 19 75 518 612 3.10% 0.59 0.0428
(0.35,0.99)
1ALT, AST or bilirubin more than twice the upper limit of the normal range.
2ALT, AST or bilirubin above the upper limit of the normal range and less than twice the upper limit of normal.
3ALT, AST and bilirubin within the normal range.
doi:10.1371/journal.pone.0085905.t003
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than in older groups. The association with gender is different from
that seen in other studies, we did not find any gender-related
predisposing factors which might explain the gender difference.
Some studies [27,40,41] have shown that the women are at an
increased risk of developing drug-induced hepatotoxicity during
treatment of TB, but most studies did not find an association with
gender [17,18,23,25,26,28,29,32,34,36,42,43].
Acetylator status was associated with drug-induced hepatotox-
icity, as has been reported in a number of previous studies
[16,18,20–22,24–26,28,44–47]. The genetic variant of NAT2*5
was associated with ATLI, in contrast to results from two recent
case-control studies in TB patients in the Chinese Han population
[19,31] which did not find an association of four common SNPs
with ATLI. However the association was weak and the sensitivity
of the markers studied for identifying persons with ATLI was low.
Table 4. Prevalence of ATLI according to N-acetyltransferase 2 (NAT2) genotype.
Genotype
Patients
With
ATLI
Patients with
elevated ALT,
AST, or bilrubin
Patients with normal
ALT, AST and
bilirubin levels Total
Prevalence
of
ATLI %
Prevalence
ratio
(95% CI) P-value#
NAT2*5 (rs1799929)
CC 39 158 928 1125 3.50% 1 0.0623
CT 30 81 397 508 5.90% 1.7
(1.10,2.70)
TT 2 7 62 69 2.80% 0.81
(0.20,3.30)
Allelefrequency C 76.10% 81.20%
T 23.90% 18.80%
NAT2*6 (rs1799930)
GG 35 124 801 960 3.60% 1 0.4016
GA 30 98 465 593 5.10% 1.4
(0.86,2.20)
AA 6 21 114 141 4.30% 1.2
(0.50,2.70)
Allelefrequency G 70.40% 74.90%
A 29.60% 25.10%
NAT2*7 (rs1799931)
GG 58 198 1103 1359 4.30% 1 0.8623
GA 12 45 274 331 3.60% 0.85
(0.46,1.60)
AA 1 0 20 21 4.80% 1.1
(0.16,7.70)
Allelefrequency G 90.10% 88.80%
A 9.90% 11.20%
not typed 18 461 479 3.80%
TOTAL 89 297 1858 224 4.00%
#Cochrane-Armitage test.
doi:10.1371/journal.pone.0085905.t004
Table 5. Prevalence of ATLI in patients according to acetylator status.
Acetylator status:
Patients
With
ATLI
Patients with
elevated ALT,
AST, or bilrubin
Patients with normal
ALT, AST and
bilirubin levels Total
Prevalence
of
ATLI %
Prevalence
ratio
(95% CI) P-value#
Rapid (RA) 9 41 287 337 2.70% 1 0.0616
Intermediate (IA) 34 118 667 819 4.20% 1.60 (0.75,3.20)
Slow (SA) 28 79 422 529 5.30% 2.00 (0.95,4.20)
not typed 18 59 482 559 3.20%
TOTAL 89 297 1858 2244 4.00%
#Cochrane-Armitage test for trend.
doi:10.1371/journal.pone.0085905.t005
Genetic Polymorphisms of NAT2, CYP2E1, GSTM1, GSTT1
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e85905
We employed the same case definition for ATLI used in a number
of previous studies. When more restrictive definitions were used,
the number of cases was reduced but the predictive value of the
genetic markers remained low.
A limitation of the present study is that although before starting
anti-tuberculosis therapy, it is normal practice for liver and renal
function to be tested, it was not possible to confirm that these tests
were performed it is therefore the possibility that some patients
had signs of liver disease that were missed when treatment started
cannot be ruled out, we did not have detailed information about
adherence, and there may be residual confounding due to
uncontrolled risk factors for liver disease, although alcohol
consumption is unlikely to be an important factor in this muslim
population. In addition, other plausible candidate genes associated
with the ATLI need to be explored [48].
The disposition of anti-tuberculosis drug is related to the activity
of many drug-metabolizing enzymes (DMEs), including NAT2,
CYP2E1and GST. Polymorphisms of some encoding genes may
influence the activity of the corresponding DMEs. In view of
NAT2*5(C481T, rs1799929), NAT2*6 (G590A, rs1799930)and
NAT2*7(G857A, rs1799931) mutations accounted for virtually all
of the slow acetylator alleles in Asians, we have evaluated the roles
of NAT2*5, NAT2*6 and NAT2*7 in the developing of ATLI
basing on our community-based TB patients. The present study
Table 6. Prevalence of ATLI by NAT genotype.
Acetylator
status Genotype
Patients
With
ATLI
Patients with
elevated ALT,
AST, or bilrubin
Patients with normal
ALT, AST and
bilirubin levels Total
Prevalence
of
ATLI %
Prevalence
ratio
(95% CI)
Rapid NAT2*4/4 9 41 287 337 2.7% 1.00
Intermediate NAT2*4/5 12 41 231 284 4.2% 1.58 (0.68,3.70)
NAT2*4/6 16 54 285 355 4.5% 1.69 (0.76,3.80)
NAT2*4/7 6 23 151 180 3.3% 1.25 (0.48,3.30)
Slow NAT2*5/5 2 7 62 71 2.8% 1.05 (0.25,4.50)
NAT2*5/6 13 31 113 157 8.3% 3.10 (1.20,8.00)
NAT2*5/7 5 8 51 64 7.8% 2.93 (0.59,15.00)
NAT2*6/6 6 20 111 137 4.4% 1.64 (0.64,4.20)
NAT2*6/7 1 13 67 81 1.2% 0.46 (0.06,3.90)
NAT2*7/7 1 0 18 19 5.3% 1.97 (0.25,15.00)
not typed 18 59 482 559 3.2%
TOTAL 89 297 1858 2244 4.0%
doi:10.1371/journal.pone.0085905.t006
Table 7. Genetic polymorphisms of CYP2E1,GSTM1 and GSTT1 and the prevalence of ATLI.
Variant
Patients
With
ATLI
Patients with
elevated ALT,
AST, or bilrubin
Patients with normal
ALT, AST and
bilirubin levels
Prevalence
of
ATLI %
Prevalence
ratio
(95% CI) P-value*
CYP2E1 Rsa I C1/C1 58 198 1066 4.40% 1 0.4708
(rs2031920): C1/C2 12 41 267 3.80% 0.85(0.46,1.57 )
C2/C2 0 2 26 0.00% 0
not typed 19 56 499
Allele frequency: C1 91.40% 88.30%
C2 8.60% 11.70%
GSTM: GSTM1*1 34 116 669 4.20% 1 0.527
GSTM1null 41 133 792 4.20% 1.02 (0.66,1.60)
not typed 14 48 397
GSTT: GSTT1*1 57 193 1041 4.40% 1 0.4627
GSTT1null 18 57 420 3.60% 0.82 (0.49,1.40)
not typed 14 47 397
GSTM1/GSTT1: M1*1/T1*1 23 89 502 3.70% 1 0.2289
M1*1/T1null 11 27 167 5.40% 1.40 (0.71,2.90)
M1null/T1*1 34 103 539 5.00% 1.30 (0.69,2.60)
M1null/T1null 7 30 253 2.40% 0.64 (0.29,1.40)
*Cochrane-Armitage test.
doi:10.1371/journal.pone.0085905.t007
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did not find NAT2*6 and NAT2*7 were risk for developing
ATLI,while other studies [18,44,45,49] have reported NAT2*6
and NAT2*7 had a higher incidence of drug-induced hepatotox-
icity. However, the association of NAT2*5 and ATLI observed in
our study population, agrees with findings of Possuelo LG et al., in
southern Brazil [44].
Acetylation activity in vitro is ranked in the sequence:-
NAT2*4.NAT2*7.NAT2*6.NAT2*5 [16,46]. The NAT2*5
mutant homogeneous genotype has not been reported in some
previous studies [19,47,49], but in Uyghur patients NAT2*5 is the
predominant allele with low acetylation activity. Slow acetylators
homozygous for the NAT2*5 allele may acetylate isoniazid more
slowly. This is in line with our finding that slow acetylators with
NAT2*5/6 has a significantly higher risk of anti-tuberculosis drug-
induced hepatitis than other genotypes.
These results may reflect ethnic differences. The proportion of
rapid, intermediate and slow acetylators in this study (21%, 49%
and 31% respectively) differs from that reported for the healthy
Chinese population [50] (30%,45% and 25%) and from other
results [19]. This may be due to the presence of other
polymorphisms in the NAT2 gene. Studying other polymor-
phisms, such as NAT2*12 and NAT2*13, may help to clarify these
conflicting results.
Among several CYP2E1 genetic polymorphisms, the RsaI
polymorphism has been evaluated mostly in association with
ATLI, explained by a higher CYP2E1 activity with the c1/c1
genotype and the inhibitory effect of INH [17,26,29,45,51]. Some
studies have shown the relationship between the CYP2E1 RsaI
c1/c1genotype and the risk of anti-TB drug-induced hepatitis
[17,23,26,43,51,52].
Huang et al. [23] in a Taiwanese population demonstrated that
the CYP2E1 c1/c1 genotype increased the risk of anti-TB drug-
induced hepatotoxicity, and similar results have been found in
China [17]. Other studies found conflicting results [18,24,25,27–
31,53]. Two recent studies in China showed no evidence of
association between CYP2E1 c1/c1 genotype and ATLI [24,31].
In our study, the CYP2E1 mutant genotype was rare and therefore
unlikely to be useful as a predictor of ATLI risk.
GST, which plays an important protective role in preventing
ATLI, exists in several isoforms. [10,54] Some genetic loci,
notably GSTM1 and GSTT1, are polymorphic. Homozygous
‘null’ mutations result in a complete absence of enzyme activity. It
is speculated that people with null GSTM1 or GSTT1 genotypes
could not detoxify the toxic reactive metabolites efficiently, and
thus have higher risk of ATLI. Some studies have reported a
relationship between GSTM1 null [17,29–38] and GSTT1[29–
38] null genotype, and ATLI. However, most of these studies [29–
34] found no evidence of an association, including studies in the
Chinese population.
According to the model of the pathogenesis of drug-induced
hepatotoxicity proposed by Russmann et al., the biochemical
mechanism of drug-induced hepatotoxicity may involve a complex
interplay between the chemical properties of the drug, environ-
mental factors (such as age, sex, diet, alcohol consumption,
compliance of drug intake, existing liver disease, concomitant use
of other drugs and comorbid illness) and genetic factors that
control the handling of the drug (metabolism, detoxification, and
transport), as well as those that influence cell injury and repair
[55]. The development of pharmacogenomics enables more
extensive studies using larger sample sizes and high-throughput
DNA microarrays, which may include more genotypes of relevant
DMEs [15]. Most previous studies have been based on the INH
metabolic pathway [56], but INH, RMP and PZA are all
hepatotoxic drugs [57] and different may have different patho-
genic mechanisms [58]. Other factors may influence gene
expression transcription and translation of CYP2E1. Gene
methylation may influence the expression of CYP [59]. Vieira
et al. [60] reported an association between CYP2E1 transcripts
and decreased methylation of CpG residues in intron 1 of the
CYP2E1gene, during the late neonatal period. In addition
microRNA (miRNA) regulation of CYP has been described [59].
Human CYP2E1 expression is regulated by miR-378, mainly via
translational repression [61]. Some studies indicate that a mutant
C allele of manganese superoxide dismutase, the absence of HLA-
DQA1*0102 and the presence of HLA-DQA1*0102 alleles, may be
associated with ATLI [37,62]. The biochemical mechanism and
pathogenesis of ATLI is complex and multifactorial, it may be
valuable to combine several risk factors to identify patients at
increased risk of ATLI.
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